Update
$Pulse Biosciences (PLSE.US)$ Reuters· 1 min ago
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study With Its Nano-Pfa Cardiac Surgery System
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study With Its Nano-Pfa Cardiac Surgery System
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Boxman : Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment